Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Predictors of stopping chemotherapy early and short survival in patients with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) who have had =3 lines of prior chemotherapy: The GCIG symptom benefit study (SBS).
Predictors of stopping chemotherapy early and short survival in patients with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) who have had =3 lines of prior chemotherapy: The GCIG symptom benefit study (SBS). Roncolato, F., Joly, F., O'Connell, R., Lanceley, A., Heitz, F., Buizen, L., Okamoto, A., Aotani, E., Salutari, V., Donnellan, P. P., Oza, A. M., AvalI-Lundqvist, E., Berek, J. S., Hilpert, F., Feeney, A., Roemer-Becuwe, C., Stockier, M. R., King, M., Friedlander, M. AMER SOC CLINICAL ONCOLOGY. 2017View details for DOI 10.1200/JCO.2017.35.15_suppl.5575
View details for Web of Science ID 000411931704053